Tag: HNPCC

Level of resistance to the HER2-targeted antibody trastuzumab is a significant clinical concern in the treating HER2-overexpressing metastatic breasts malignancy. on trastuzumab treatment. 1. Intro Trastuzumab (Herceptin; Genentech, SAN FRANCISCO BAY AREA, CA) is certainly a humanized monoclonal antibody against an epitope in the extracellular area from the HER2 receptor tyrosine kinase proteins [1]. HER2…